Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucent-J: Luseogliflozin and Myocardial Flow Reserve in Type 2 Diabetes
jRCTs051220016Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in myocardial flow reserve (MFR) at 24 weeks between groups. Started Aug 2022; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220016.